EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY

Chronic Kidney Diseases Clinical Trial

Official title:

PROTECTIVE EFFECT OF SGLT2 INHIBITORS ON POST-CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY IN DIABETIC AND CKD PATIENTS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06288529
• Other study ID #: 1
• Status: Completed
• Start date: July 15, 2023
• Est. completion date: January 31, 2024

Study information

• Verified date: July 2023
• Source: University of Health Sciences Balikesir Hospital Eduation and Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic kidney disease and type 2 diabetes mellitus patients are with in high-risk patients in coronary arterial diseases and increasing number of coronary angiography and coronary interventional procedures have been performed in these population. As well as the risk factors have been identified by many studies preventive measures are lacking. In our study we found that SGLT2 inhibitors are beneficial in terms of reducing contrast media induced acute kidney injury in both diabetic and CKD patients.This is one of the leading studies in the literature pointing that SGLT2 inhibitors may have a potentially beneficial role in reducing or preventing the development of PC-AKI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 975
• Est. completion date: January 31, 2024
• Est. primary completion date: December 31, 2023
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients who underwent coronary artery imaging or percutaneous coronary intervention procedures using contrast media
• Patient ages were between 18 and 75 years
• Estimated glomerular filtration rates (eGFRs) between 25 and 115

Exclusion Criteria:

• Patients with acute myocardial infarction, acute renal injury, history of kidney transplantation, severe heart failure (HF, New York Heart Association IV), malignancy, also patients who received other PC-AKI preventive medications like as N-acetylcysteine, sodium bicarbonate, or incomplete medical records were excluded from the analyses.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Chronic Kidney Diseases
• Kidney Diseases
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
Turkey	University of Health Sciences Balikesir Education and Research Hospital	Balikesir

Sponsors (1)

Lead Sponsor	Collaborator
University of Health Sciences Balikesir Hospital Eduation and Research

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Development of post-contrast acute kidney injury	The impairment of renal function which is measured as either a 25% rise in serum creatinine level from baseline or an increase of 0.5 mg/dL (44 µmol/L) in absolute serum creatinine level.	Within 48-72 hours following intravenous contrast medium administration.